Despite extensive research, the origins of COVID-19 remain elusive. In a new study published in the KeAi journal Advances in Biomarker Sciences and Technology (ABST), an AI-driven approach was adopted ...
A new case report details a novel genetic mutation linked to drug resistance in a non-small cell lung cancer patient ...
News Medical on MSN4d
RUFY1-RET fusion identified as mechanism of resistance to lorlatinib in lung cancerA new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled "Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 ...
The New England Journal of Medicine has published results from the Phase II eNRGy trial for Bizengri (zenocutuzumab), a novel cancer med from Merus. Bizengri is the first approved treatment for people ...
The American Cancer Society estimates that 83,000 new cases of bladder cancer will be diagnosed this year, with nearly 17,000 ...
Zenocutuzumab helps fill an important need for patients with advanced pancreatic cancer and NSCLC with NRG1 gene fusions, said Alison Schram M.D., ...
A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “Acquired RUFY1-RET rearrangement as a ...
5d
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 05, 2025(Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodi ...
Scientists use laser technology and robotics to study fusion fuel retention in the JET reactor to unlock the secrets of ...
This manuscript describes an important finding of the transcriptional control of a chimeric gene transfer agents (GTA) cluster in Bartonella by a processive anti-termination factor (BrrG). The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback